{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:39:54Z","timestamp":1790764794722,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,31]],"date-time":"2021-01-31T00:00:00Z","timestamp":1612051200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2017YFC1308900"],"award-info":[{"award-number":["2017YFC1308900"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["NCT03713905"],"award-info":[{"award-number":["NCT03713905"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.ejca.2021.01.020","type":"journal-article","created":{"date-parts":[[2021,3,7]],"date-time":"2021-03-07T06:08:05Z","timestamp":1615097285000},"page":"1-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Dose escalation and expansion (phase Ia\/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma"],"prefix":"10.1016","volume":"148","author":[{"given":"Dan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunguang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifang","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingwei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peijian","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxian","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ou","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guojun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Ba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianji","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanzhi","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianli","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bangwei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqing","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiying","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsheng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yabing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongyuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyuan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8798-4756","authenticated-orcid":false,"given":"Lin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejca.2021.01.020_bib1","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2146\/ajhp140768","article-title":"Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma[J]","volume":"73","author":"Ivashko","year":"2016","journal-title":"Am J Health Syst Pharm"},{"issue":"21","key":"10.1016\/j.ejca.2021.01.020_bib2","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2021.01.020_bib3","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1177\/2040620718761777","article-title":"Pembrolizumab and its role in relapsed\/refractory classical Hodgkin's lymphoma: evidence to date and clinical utility[J]","volume":"9","author":"Shindiapina","year":"2018","journal-title":"Therapeutic Advances in Hematology"},{"issue":"7","key":"10.1016\/j.ejca.2021.01.020_bib4","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/14712598.2020.1749593","article-title":"Nivolumab for the treatment of hepatocellular carcinoma[J]","volume":"20","author":"Woon","year":"2020","journal-title":"Expet Opin Biol Ther"},{"key":"10.1016\/j.ejca.2021.01.020_bib5","series-title":"KEYNOTE-045: randomized phase 3 trial of pembrolizumab (MK-3475) versus paclitaxel, docetaxel, or vinflunine for previously treated metastatic urothelial cancer[J]","author":"Bellmunt","year":"2015"},{"issue":"10111","key":"10.1016\/j.ejca.2021.01.020_bib6","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial[J]","volume":"390","author":"Yoon-Koo","year":"2017","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ejca.2021.01.020_bib7","doi-asserted-by":"crossref","first-page":"173","DOI":"10.21037\/atm.2016.03.34","article-title":"The emerging role of immune-therapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications[J]","volume":"4","author":"Panagiota","year":"2016","journal-title":"Ann Transl Med"},{"issue":"4","key":"10.1016\/j.ejca.2021.01.020_bib8","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1001\/jamaoncol.2018.5441","article-title":"Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE-180 study[J]","volume":"5","author":"Shah","year":"2019","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2021.01.020_bib9","first-page":"81","article-title":"Review article: biologics, immunotherapy, and future directions in the treatment of advanced cholangiocarcinoma[J]","volume":"18","author":"Saeed","year":"2019","journal-title":"Clin Colorectal Canc"},{"key":"10.1016\/j.ejca.2021.01.020_bib10","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat Rev Canc"},{"key":"10.1016\/j.ejca.2021.01.020_bib11","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2018-4561","article-title":"Abstract 4561: preclinical characterization of GLS-010 (AB122): a fully humanized clinical-stage anti-PD-1 antibody","volume":"78","author":"Tan","year":"2018","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2021.01.020_bib12","doi-asserted-by":"crossref","DOI":"10.1186\/s13000-016-0545-8","article-title":"Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma[J]","volume":"11","author":"Rebelatto","year":"2016","journal-title":"Diagn Pathol"},{"issue":"2","key":"10.1016\/j.ejca.2021.01.020_bib13","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.juro.2017.11.024","article-title":"Re: safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer[J]","volume":"199","author":"Chang","year":"2018","journal-title":"J Urol"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2021.01.020_bib14","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2019.37.15_suppl.4079","article-title":"Pembrolizumab (pembro) for advanced biliary adenocarcinoma: results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies[J]","volume":"37","author":"Bang","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2021.01.020_bib15","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1158\/1078-0432.CCR-19-2443","article-title":"Safety and efficacy of durvalumab and tremelimumab alone or in combination in patients with advanced gastric and gastroesophageal junction adenocarcinoma[J]","volume":"26","author":"Kelly","year":"2020","journal-title":"Clin Canc Res: an official journal of the American Association for Cancer Research"},{"issue":"10","key":"10.1016\/j.ejca.2021.01.020_bib16","article-title":"Predictive factors for response to PD-1\/PD-L1 checkpoint inhibition in the field of hepatocellular carcinoma: current status and challenges[J]","volume":"11","author":"Jilkova","year":"2019","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.ejca.2021.01.020_bib17","article-title":"Phase Ia\/Ib study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors [J]","author":"Desai","year":"2020","journal-title":"J ImmunoTherapy of Cancer"},{"key":"10.1016\/j.ejca.2021.01.020_bib18","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s40264-018-0774-8","article-title":"Safety and tolerability of immune checkpoint inhibitors (PD-1 and PD-L1) in cancer","volume":"42","author":"Baraibar","year":"2019","journal-title":"Drug Saf"},{"key":"10.1016\/j.ejca.2021.01.020_bib19","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.0013","article-title":"Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial","volume":"4","author":"Fuchs","year":"2018","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2021.01.020_bib20","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1093\/annonc\/mdz197","article-title":"Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD1 antibody in phase Ib\/II clinical trial NCT02915432[J]","volume":"30","author":"Wang","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.01.020_bib21","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastroesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a ran-domized, double blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2021.01.020_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.00673","article-title":"Association between tumor mutation burden (TMB) and outcomes of cancer patients treated with PD-1\/PD-L1 inhibitions: a meta-analysis[J]","volume":"10","author":"Zhu","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ejca.2021.01.020_bib23","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.lungcan.2017.08.005","article-title":"PD-L1 expression in advanced NSCLC: insights into risk stratification and treatment selection from a systematic literature review[J]","author":"Brody","year":"2017","journal-title":"Lung Canc"},{"key":"10.1016\/j.ejca.2021.01.020_bib24","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.ccell.2018.04.001","article-title":"Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer","volume":"33","author":"Hellmann","year":"2018","journal-title":"Canc Cell"},{"key":"10.1016\/j.ejca.2021.01.020_bib25","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.ejca.2021.01.020_bib26","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 expression as a predictive biomarker in cancer immunotherapy[J]","volume":"14","author":"Patel","year":"2015","journal-title":"Mol Canc Therapeut"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492100040X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492100040X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T06:53:04Z","timestamp":1778568784000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980492100040X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":26,"alternative-id":["S095980492100040X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.01.020","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dose escalation and expansion (phase Ia\/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.01.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}